Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.48 |
| ▸ | CDC25B | P30305 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | SNCA | P37840 | 2/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216271 | 0.75 | MAOA (0.42) | IDO1CDC25BMAOAMAOBSNCA | |
| SCHEMBL670373 | 0.75 | EHMT2 (0.40) | IDO1CDC25BMAOAMAOBSNCA | |
| SCHEMBL20483611 | 0.72 | MEN1 (0.37) | IDO1CDC25BMAOAMAOBSNCA | |
| SCHEMBL7832139 | 0.70 | S100A4 (0.55) | CDC25BMEN1KMT2AMAPTBLM | |
| SCHEMBL2095985 | 0.69 | KMT2A (0.50) | IDO1CDC25BMAOAMAOBSNCA | |
| SCHEMBL415465 | 0.67 | MEN1 (0.42) | IDO1CDC25BMAOAMAOBSNCA | |
| SCHEMBL725425 | 0.67 | MEN1 (0.45) | IDO1CDC25BMAOAMAOBSNCA | |
| Naphthoquinone SCHEMBL29354680 | 0.66 | IDO1 (1.00) | IDO1CDC25BMAOAMAOBSNCA | |
| Naphthoquinone SCHEMBL11359780 | 0.66 | IDO1 (1.00) | IDO1CDC25BMAOAMAOBSNCA | |
| Naphthoquinone SCHEMBL8861335 | 0.66 | IDO1 (1.00) | IDO1CDC25BMAOAMAOBSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023249805-A1 | CO2 PURIFICATION SYSTEM AND METHOD USING CO2-ABSORBING ELECTRODE CELLS COMBINED WITH PURE CO2 REDUCTION IN AN ELECTROLYZER TO PRODUCE CARBON CONTAINING PRODUCTS | TWELVE BENEFIT CORPORATION (US) | 2023-12-28 | — | — | WO | claimed |
| US-20230415104-A1 | CO2 PURIFICATION WITH ELECTROACTIVE POLYMERS | TWELVE BENEFIT CORPORATION | 2023-12-28 | — | — | US | claimed |
| EP-3078717-B1 | PHOTOBASE GENERATOR | SAN APRO LTD (JP) | 2020-05-20 | — | — | EP | claimed |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-06-27 | — | — | US | claimed |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-10-04 | — | — | US | claimed |
| US-20120035158-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-02-09 | — | — | US | claimed |
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | US | claimed |
| EP-2298769-A1 | Xanthin derivatives, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | claimed |
| US-20100173916-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | US | claimed |
| US-7569574-B2 | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | claimed |
| EP-1101759-A1 | PHENYLAZOLE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND DRUGS FOR HYPERLIPEMIA | NIPPON SODA CO., LTD. (JP) | 2001-05-23 | — | — | EP | claimed |
| US-5804601-A | USEFUL FOR TREATING ALZHEIMER'S DISEASE, MULTIPLE SCLEROSIS, BACTERIAL OR VIRAL MENINGITIS, DOWN'S SYNDROME AND PARKINSON'S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-08 | — | — | US | claimed |
| EP-0737671-A2 | Aromatic hydroxamic acid compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1996-10-16 | — | — | EP | claimed |
| US-4140681-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1979-02-20 | — | — | US | claimed |
| US-4131673-A | INHIBITION AND SUPPRESSION OF THROMBOSIS IN MAMMALS | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1978-12-26 | — | — | US | claimed |
| US-4125604-A | PEPTIDES, ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1978-11-14 | — | — | US | claimed |
| US-4101653-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1978-07-18 | — | — | US | claimed |
| US-4097472-A | INHIBITION AND SUPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-06-27 | — | — | US | claimed |
| US-4093712-A | ANTITHROMBOGENIC AGENTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JA) | 1978-06-06 | — | — | US | claimed |
| US-4066773-A | ANTITHROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1978-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | IDO1 418/4885CDC25B 4241/4885MAOA 409/4885 |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | IDO1 418/4885CDC25B 4241/4885MAOA 409/4885 |
| US-20100173916-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | IDO1 418/4885CDC25B 4241/4885MAOA 409/4885 |
| US-20120035158-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | IDO1 418/4885CDC25B 4241/4885MAOA 409/4885 |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | IDO1 418/4885CDC25B 4241/4885MAOA 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.